{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:18:33Z","timestamp":1762323513648,"version":"3.37.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T00:00:00Z","timestamp":1340150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["DMR-100-110","DMR-101-080"],"award-info":[{"award-number":["DMR-100-110","DMR-101-080"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taiwan Department of Health Clinical Trial and Research Center for Excellence","award":["DOH101-TD-B-111-004"],"award-info":[{"award-number":["DOH101-TD-B-111-004"]}]},{"name":"Taiwan Department of Health Cancer Research Center for Excellence","award":["DOH101-TD-C-111-005"],"award-info":[{"award-number":["DOH101-TD-C-111-005"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:Describe the effect of finasteride use on the incidence of prostate cancer and overall cancer.Describe the effect of dutasteride use on the incidence of renal cancer.Explain the relationship between finasteride dosage and risk of prostate cancer and overall cancer risk.<\/jats:p>\n                  <jats:p>CME This article is available for continuing medical education credit at CME.TheOncologist.com<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>5\u03b1-Reductase inhibitors (5ARIs) are commonly used to treat benign prostate hyperplasia (BPH) by blocking the conversion of testosterone into the more potent dihydrotestosterone. This study explored a possible association between the use of the 5ARIs finasteride and dutasteride and the subsequent risk of prostate cancer or other cancers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>We analyzed data from the Taiwanese National Health Insurance system. In a BPH cohort, we identified 1,489 patients with cancer and included them in our study group. For the control group, 3 patients without cancer were frequency matched with each BPH case for age, BPH diagnosis year, index year, and month. Information regarding past 5ARI use was obtained from the Taiwanese National Health Insurance Research Database (NHIRD). Multivariate logistic regression analysis was conducted, and odds ratio (OR) and 95% confidence interval (CI) were estimated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Finasteride use marginally increased the incidence of prostate and overall cancer at a level of statistical significance (prostate cancer: OR = 1.90; 95% CI: 1.00\u20133.59; overall cancer: OR = 1.51; 95% CI: 1.00\u20132.28). Dutasteride use significantly increased kidney cancer risk (OR = 9.68, 95% CI: 1.17\u201380.0). Dosage analysis showed that lower doses of finasteride were associated with higher overall and prostate cancer risks. The major limitation is the lack of important data in the NHIRD, such as prostate cancer histologic grades, smoking habits, alcohol consumption, body mass index, socioeconomic status, and family history of cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>This population-based nested case-control study suggested that finasteride use may increase prostate and overall cancer risks for patients with BPH. The effects were more prominent for patients using lower doses of finasteride.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0464","type":"journal-article","created":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T13:58:04Z","timestamp":1340287084000},"page":"986-991","source":"Crossref","is-referenced-by-count":5,"title":["A Population-Based Nested Case-Control Study in Taiwan: Use of 5\u03b1-Reductase Inhibitors Did Not Decrease Prostate Cancer Risk in Patients with Benign Prostate Hyperplasia"],"prefix":"10.1093","volume":"17","author":[{"given":"Ji-An","family":"Liang","sequence":"first","affiliation":[{"name":"a Institute of Clinical Medicine Science and School of Medicine, College of Medicine, College of Public Health, China Medical University, Taichung, Taiwan"},{"name":"d Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Min","family":"Sun","sequence":"additional","affiliation":[{"name":"g Department of Radiation Oncology, Zuoying Armed Forces General Hospital, Kaohsiung, Taiwan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chia","family":"Lin","sequence":"additional","affiliation":[{"name":"h Department of Nuclear Medicine, E-DA Hospital, Kaohsiung, Taiwan; China Medical University, Taichung, Taiwan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Ni","family":"Chang","sequence":"additional","affiliation":[{"name":"b Program for Cancer Biology and Drug Discovery, College of Public Health, China Medical University, Taichung, Taiwan"},{"name":"c Institute of Environmental Health, College of Public Health, China Medical University, Taichung, Taiwan;"},{"name":"e Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan"},{"name":"i Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fung-Chang","family":"Sung","sequence":"additional","affiliation":[{"name":"c Institute of Environmental Health, College of Public Health, China Medical University, Taichung, Taiwan;"},{"name":"e Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hsin","family":"Muo","sequence":"additional","affiliation":[{"name":"c Institute of Environmental Health, College of Public Health, China Medical University, Taichung, Taiwan;"},{"name":"e Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hung","family":"Kao","sequence":"additional","affiliation":[{"name":"a Institute of Clinical Medicine Science and School of Medicine, College of Medicine, College of Public Health, China Medical University, Taichung, Taiwan"},{"name":"f Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,6,20]]},"reference":[{"key":"2021122308161047700_B1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1432-0436.2008.00274.x","article-title":"Gene expression profiling in the developing prostate","volume":"76","author":"Pritchard","year":"2008","journal-title":"Differentiation"},{"key":"2021122308161047700_B2","doi-asserted-by":"crossref","first-page":"11890","DOI":"10.1073\/pnas.182376299","article-title":"The program of androgen-responsive genes in neoplastic prostate epithelium","volume":"99","author":"Nelson","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122308161047700_B3","first-page":"S31","article-title":"Comparison of clinical trials with finasteride and dutasteride","volume":"6","author":"Nickel","year":"2004","journal-title":"Rev Urol"},{"key":"2021122308161047700_B4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1056\/NEJMp1106783","article-title":"The risks and benefits of 5\u03b1-reductase inhibitors for prostate-cancer prevention","volume":"365","author":"Theoret","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122308161047700_B5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122308161047700_B6","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122308161047700_B7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jjco\/hyq221","article-title":"Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study","volume":"41","author":"Akaza","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"2021122308161047700_B8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1377\/hlthaff.22.3.77","article-title":"Does universal health insurance make health care unaffordable? Lessons from Taiwan","volume":"22","author":"Lu","year":"2003","journal-title":"Health Aff (Millwood)"},{"volume-title":"Taiwan Cancer Registry","author":"Cancer Statistics Annual Report","key":"2021122308161047700_B9"},{"key":"2021122308161047700_B10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/cncr.24760","article-title":"Annual report to the nation on the status of cancer, 1975\u20132006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates","volume":"116","author":"Edwards","year":"2010","journal-title":"Cancer"},{"key":"2021122308161047700_B11","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ejca.2004.12.033","article-title":"Changing demography of prostate cancer in Asia","volume":"41","author":"Sim","year":"2005","journal-title":"Eur J Cancer"},{"key":"2021122308161047700_B12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/jjco\/hyr051","article-title":"The association between malignancy and end-stage renal disease in Taiwan","volume":"41","author":"Liang","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"2021122308161047700_B13","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0140-6736(92)90927-U","article-title":"5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males","volume":"339","author":"Ross","year":"1992","journal-title":"Lancet"},{"key":"2021122308161047700_B14","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1073\/pnas.94.7.3320","article-title":"The CAG repeat within the androgen receptor gene and its relationship to prostate cancer","volume":"94","author":"Giovannucci","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122308161047700_B15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pros.10108","article-title":"Hormones and prostate cancer: current perspectives and future directions","volume":"52","author":"Hsing","year":"2002","journal-title":"Prostate"},{"key":"2021122308161047700_B16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.beem.2008.01.016","article-title":"5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction","volume":"22","author":"Rittmaster","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2021122308161047700_B17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0090-4295(98)00184-8","article-title":"Treatment with finasteride preserves usefulness of prostate specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo controlled clinical trial","volume":"52","author":"Andriole","year":"1998","journal-title":"Urology"},{"volume-title":"Prostate cancer (CAP) detection in the medical therapy of prostatic symptoms (MTOPS) trial","year":"2003","author":"Andriole","key":"2021122308161047700_B18"},{"key":"2021122308161047700_B19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.urology.2011.03.063","article-title":"Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial","volume":"78","author":"Roehrborn","year":"2011","journal-title":"Urology"},{"key":"2021122308161047700_B20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1743-6109.2010.02157.x","article-title":"Adverse side effects of 5\u03b1-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients","volume":"8","author":"Traish","year":"2011","journal-title":"J Sex Med"},{"key":"2021122308161047700_B21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1741-7015-9-105","article-title":"5-\u03b1 reductase inhibitors and prostate cancer prevention: where do we turn now?","volume":"9","author":"Hamilton","year":"2011","journal-title":"BMC Med"},{"key":"2021122308161047700_B22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-3-642-10858-7_9","article-title":"Prostate cancer prevention with 5 alpha-reductase inhibitors","volume":"188","author":"Parekh","year":"2011","journal-title":"Recent Results Cancer Res"},{"key":"2021122308161047700_B23","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1158\/1055-9965.EPI-10-0082","article-title":"Knowledge and use of finasteride for the prevention of prostate cancer","volume":"19","author":"Hamilton","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122308161047700_B24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.urology.2007.01.051","article-title":"Study of prostate cancer pathologic features in Chinese populations","volume":"69","author":"Chuang","year":"2007","journal-title":"Urology"},{"key":"2021122308161047700_B25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0753-3322(96)82658-8","article-title":"Finasteride: a clinical review","volume":"49","author":"Gormley","year":"1995","journal-title":"Biomed Pharmacother"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0464","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0464","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/7\/986\/41859109\/oncolo_17_7_986.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/7\/986\/41859109\/oncolo_17_7_986.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T20:54:48Z","timestamp":1640292888000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/7\/986\/6403294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,20]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,6,20]]},"published-print":{"date-parts":[[2012,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0464","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2012,7,1]]},"published":{"date-parts":[[2012,6,20]]}}}